P2RY12 and chronic kidney disease: Studies focusing on type of P2Y12-inhibitor prior studies have shown contradictory results: While in the CLARITY-TIMI-28 trial [28], which compared clopidogrel to placebo, showed that patients with CKD did not benefit from clopidogrel, a subgroup-analysis form the TRITON-TIMI-38-trial [29], which compared prasugrel to clopidogrel showed, that the risk reduction in patients with no CKD was more pronounced at 20%, while patients with CKD (GFR < 60 ml/min) showed a reduction of 14%.